Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Alanoud M Alyousef"'
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology
Hessah F BinJadeed,1 Alanoud M Alyousef,1 Fahad M Alsaif,2 Ahmed A Alhumidi,3 Homaid O Alotaibi2 1College of Medicine, King Saud University, Riyadh, Saudi Arabia, 2Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99444d55d18ed9dd940fe50ecff9b001
https://pubmed.ncbi.nlm.nih.gov/29731653
https://pubmed.ncbi.nlm.nih.gov/29731653
Autor:
Leena Zeitouni, Albatool Alamari, Alanoud M Alyousef, Nouf S Alballa, Fahad Alsaif, Mohammed Ayesh Zayed, Ahmed Alhumidi
Publikováno v:
AME Case Reports. 2:49-49
Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian cell expression system and is widely-known to treat a number of immune-mediated conditions, inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e5481709924f78cd8e50c7c09236fb
https://doi.org/10.21037/acr.2018.12.01
https://doi.org/10.21037/acr.2018.12.01